Brief: Exicure And Bluejay Therapeutics Enter Into A Patent License Agreement To Develop Cavrotolimod For The Treatment Of Hepatitis

Exicure

05/02/2024 21:04

Feb 5 (Reuters) - Exicure Inc  XCUR.O :
    * EXICURE, INC. AND BLUEJAY THERAPEUTICS INC. ENTER INTO A
PATENT
LICENSE AGREEMENT TO DEVELOP CAVROTOLIMOD FOR THE TREATMENT OF
HEPATITIS
    * EXICURE INC - BLUEJAY WILL RECEIVE AN EXCLUSIVE LICENSE IN
FIELD
OF HEPATITIS TO ALL OF EXICURE'S RELEVANT PATENTS
    * EXICURE INC - BLUEJAY PAID EXICURE AN INITIAL SMALL,
ONE-TIME
PAYMENT AFTER EXECUTION OF THIS AGREEMENT
    * EXICURE INC - EXICURE WILL ALSO BE ENTITLED TO MODEST
ROYALTIES
ON FUTURE NET SALES ON ALL LICENSED TECHNOLOGY BY BLUEJAY DURING
TERM OF LICENSED PATENTS
    * EXICURE INC - BLUEJAY WILL RECEIVE AN EXCLUSIVE LICENSE IN
FIELD
OF HEPATITIS TO ALL OF EXICURE'S RELEVANT PATENTS.
    * EXICURE INC - ENTITLED TO MODEST ROYALTIES ON FUTURE NET
SALES
ON ALL LICENSED TECHNOLOGY BY BLUEJAY DURING TERM OF LICENSED
PATENTS
    * EXICURE INC - BLUEJAY PAID EXICURE AN INITIAL SMALL,
ONE-TIME
PAYMENT AFTER EXECUTION OF THIS AGREEMENT.

Source text for Eikon:  ID:nBw8ymB6Xa 
Further company coverage:  XCUR.O 

 ((reuters.briefs@thomsonreuters.com;))